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As a ligand-dependent transcription factor of the nuclear hormone receptor superfamily, the pregnane X receptor
(PXR) has a multitude of functions including regulating xenobiotic and cholesterol metabolism, energy homeostasis,
gut mucosal defense, and cancer development. Whereas the detoxification functions of PXR have been widely studied
and well established, the role of PXR in cancer has become controversial. With more than 60% of non-prescription and
prescription drugs being metabolized by cytochrome P450 enzyme 3A4 (CYP3A4), a transcriptional target of PXR,
insights into the regulation of PXR during systemic administration of novel treatment modalities will lead to a
better understanding of PXR function in the context of human disease. Previous studies have suggested that PXR
activation decreases drug sensitivity and augments chemoresistance in certain colon cancers mainly through the
upregulation of CYP3A4 and multidrug resistance protein-1 (MDR1). Later studies suggest that downregulation of
PXR expression may be oncogenic in hormone-dependent breast and endometrial cancers by reducing estrogen
metabolism via CYP3A4; thus, higher estradiol concentrations contribute to carcinogenesis. These results suggest
a differential role of PXR in tumor growth regulation dependent on tissue type and tumor microenvironment.
Here, we will summarize the various mechanisms utilized by PXR to induce its diverse effects on cancerous tissues.
Moreover, current approaches will be explored to evaluate the exploitation of PXR-mediated pathways as a novel
mechanistic approach to cancer therapy.
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Xenobiotic metabolism has been described as an adap-
tive response utilized by organisms exposed to drugs or
environmental chemicals leading to induction of drug
metabolizing enzymes to enhance water solubility and
excretion [1]. Many compounds induce xenobiotic me-
tabolism via the induction of Phase I (cytochrome P-450,
or CYPs) and II enzymes, and Phase III transporters.
Phase I enzymes include heme monooxygenases that
catalyze hydroxylation or oxidation of hydrophobic com-
pounds, resulting in enhanced water solubility [2]. CYPs
are major Phase I enzymes and include CYP1A2, CYP2Cs,
CYP2E1, CYP3A4, and CYP2B6 [3]. Phase II enzymes
conjugate polar groups for detoxification and excretion
that include glucuronide, glutathione and sulfate [3]. Phase
III transporters are expressed in various tissues and are im-
portant in drug absorption, distribution, and excretion [4].* Correspondence: taosheng.chen@stjude.org
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article, unless otherwise stated.Phase III transporters include P-glycoprotein (P-gp; also
known as multidrug resistance protein-1, or MDR1),
multidrug resistance-associated proteins, and organic
transporting polypeptides [4]. Nevertheless, induction
of these drug metabolizing enzymes and transporters is
regulated at the gene transcription level [1,4,5]. Orphan
nuclear receptors are known to regulate bile acid [6], hor-
monal and lipid metabolism [7], hepatic steatosis [8], drug
toxicity interactions [9], and cancer drug resistance via the
induction of the previously mentioned metabolic enzymes
[10]. The pregnane X receptor (PXR) is a key regulator of
CYP3A gene expression [11]. Xenobiotics and steroids
have been shown to regulate CYP3A gene expression via
PXR activation [12]. Upon activation, PXR forms a hetero-
dimer with retinoic acid receptor to bind to DNA [13].
Subsequently, PXR binds to response elements within the
promoter regions of various transcriptional gene targets
containing direct repeats of TGAACT spaced by three nu-
cleotides (DR3) or four nucleotides (DR4) or an everted or
inverted repeat of the TGAACT spaced by six nucleotidesentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Tissue-specific characteristics of PXR in cancer
development













Colon cancer Yes [48] Yes [35] Yes [51]
Breast carcinoma Yes [26] Yes [37]
Hepatoma cells Yes [34]
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ligand and promoter selective regulation of PXR-mediated
gene expression [20]. In fact, different ligands of PXR can
modulate PXR binding to different response elements in
the promoter regions of targeted genes [20]. Moreover,
co-activator interactions were ligand-dependent via differ-
ences in the conformations of the PXR-ligand complexes
[20]. For example, the anticancer drugs paclitaxel and
cisplatin induced PXR binding, more strongly to re-
sponse elements within the MDR1 promoter than those
within the CYP3A4 promoter [20]. Interestingly, among
various diverse species, there is approximately 95% se-
quence homology in the DNA binding domain (DBD)
of PXR but only approximately 80% homology in the
ligand binding domain (LBD). Previous studies have re-
vealed significant interspecies differences in PXR activa-
tion profiles between human PXR (hPXR) and mouse
PXR (mPXR) [11]. For example, known PXR ligands such
as rifampicin, clotrimazole, lovastatin, and phenobarbital
were efficacious activators of hPXR, as evidenced by in-
creased CYP3A gene expression, but not mPXR. On the
other hand, pregnenolone 16α-carbonitrile was a potent
inducer of mPXR but not hPXR [11]. Initially, there
were several lines of evidence that suggested high
tissue-specific expression of PXR in liver and intestine
[3,11,14,21]. However, further studies revealed PXR ex-
pression in mouse kidney [14], ovary and uterus [22]
and in human brain [23] and breast tissues [24]. It was
later extended by Lamba and colleagues to include the
expression of PXR in stomach, adrenal glands and bone
marrow of human tissue samples [25]. Clinical rele-
vance of PXR expression is continuing to emerge and
suggest PXR is a potential therapeutic target to de-
crease tumor growth. PXR is highly expressed in certain
cancers [26-30], promoting cell proliferation and che-
moresistance [31-33], and potentially contributing to
malignancy [33] in both preclinical models and clinical
patient samples. Interestingly, PXR overexpression by
stable transfection of hPXR or by pharmacologic activa-
tion has been shown to protect cells from apoptosis in
HepG2 liver hepatocellular carcinoma [34]. Similar re-
sults were seen in HCT116 human colon cancer and
LS180 intestinal human colon adenocarcinoma cells by
overexpressing constitutively activated PXR or through
pharmacologic activation of PXR with the cognate lig-
and rifampicin [35], suggesting an anti-apoptotic role of
PXR in carcinogenesis. On the other hand, PXR has
been shown to be a regulator of apoptosis in tissues
that are outside of the metabolic realm of the liver and in-
testine, including tumor tissues within endometrial and
breast cancers [36,37]. Thus, these findings suggest novel
tissue-specific functions of PXR that warrant further ana-
lysis as a potential target of chemotherapeutic utility.
Moreover, co-activator versus co-repressor expression,tumor microenvironment, and differential ligand expres-
sion have all been shown to play key roles in the tissue-
specific functions of PXR [38]. With PXR regulating a
multitude of diverse functions to maintain cellular homeo-
stasis, targeting PXR clinically becomes a promising, yet
difficult task. Here, we focus on the differential regulation
of PXR in a tissue-specific manner and how the tissue-
specificity of expression/function may affect the overall
outcome of targeting PXR in human disease. Table 1 sum-
marizes the tissue-specific features of PXR in cancer
development.
Pro-proliferative and anti-apoptotic properties of PXR
The role of PXR in cancer has received considerable
attention due to its clinical relevance and potential
contribution to the “malignant” phenotype of cancers.
Gupta and colleagues [33] found that PXR was expressed
in human ovarian carcinoma cells (OVCAR8 and SKOV-3),
promoting cell proliferation and drug resistance through
rifampicin-mediated PXR induction of target genes. In
addition, in vivo data utilizing SKOV-3 xenografts sug-
gested that cognate ligand activation of PXR promoted
tumor growth by significantly inactivating and decreasing
cytotoxic drug concentrations via upregulation of PXR-
mediated drug-metabolizing enzymes CYP2B6, CYP3A4
and UDP glucuronosyltransferase 1A1 (UGT1A1) [33].
Similar anti-apoptotic results were translational in both
normal mouse epithelium and human colon cancer cells
[35]. Interestingly, stable viral transduction of the consti-
tutively active viral protein 16 activation domain fused to
the amino terminus of human PXR (VP-PXR) or pharma-
cologic activation via rifampicin treatment protected cells
from deoxycholic acid-induced apoptosis in colon cancer
cells, a mechanistic effect outside of the canonical PXR
xenobiotic function [35]. Furthermore, PXR overexpres-
sion promoted induction of anti-apoptotic genes, BAG3,
BIRC2, and MCL-1 and downregulated pro-apoptotic
genes BAK-1 and TP53 through both genetic (using
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rifampicin) activation of PXR [35]. These reports stress
the importance of PXR activation in the biology of hu-
man cancers.
With chemoresistance being a significant barrier to the
efficacy of chemotherapeutic drugs, understanding how
PXR may regulate cell proliferation, chemoresistance, and
tumorigenesis is needed to identify novel targets for can-
cer therapeutic drug discovery and development. It has
been well established that PXR is efficiently activated by
several steroid hormones, including estrogen, as indicated
by the induction of the CYP3A family of steroid hydroxy-
lases in both in vivo models and patient samples
[11,14,15,28,39-42]. PXR is expressed in reproductive uter-
ine and ovarian tissues, and PXR transcriptional targets
CYP3A4 and CYP3A7 play roles in steroid metabolism in
human endometrium [22,43]. Stronger nuclear staining of
PXR has been reported in samples from endometrial can-
cer patients than in normal patient endometrium samples.
Interestingly, Masuyama and colleagues [28] reported a
significant inverse relationship between PXR expression
and estrogen receptor-α (ER-α) status in endometrial can-
cer tissues. Their findings suggested higher PXR and
CYP3A4/7 expression in endometrial cancer tissues with
lower ER-α status [28]. Masuyama and colleagues [28] also
suggested that PXR-CYP3A4/7 signaling may serve as an
oncogenic alternative pathway that contributes to carcino-
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Colon carcinoma Activation of PXR enhanced cell growth, invasion, and
colon cancer xenograft models
Breast carcinoma Immunohistochemistry, quantitative reverse transc
expression in carcinoma tissues but not in nonneopla
In breast carcinoma cells, pharmacologic activatio






Colon cancer PXR activation via a genetic approach (constitutive
protected colon cancer cells from chemically induce




Agonists of PXR increased hepatocyte viability and pr
the induction of Bcl-2 and Bcl-xl in human and rat
hepatoma cells from Fas-induced a
Prostate cancer PXR activation via a potent selective PXR agonist, SR12
and vinblastine. Knockdown of PXR via shRNA decreased
Endometrial
cancer
PXR overexpression caused significant decreases i
PXR downregulation enhanced apoptosis in the presencIn other hormone-dependent neoplasms such as prostate
cancer, Chen and colleagues [32] found that PXR activa-
tion by the selective potent agonist SR12813 enhanced re-
sistance to chemotherapeutic drugs taxol and vinblastine
via PXR-mediated upregulation of CYP3A4 and MDR1 in
human prostate cancer PC3 cells. Furthermore, PXR
knockdown using shRNA constructs enhanced the che-
mosensitivity of prostate cancer cells to chemotherapeutic
drugs, suggesting a contributing role of PXR to chemore-
sistance in prostate cancer [32].
Additional studies suggest that the pro-proliferative and
anti-apoptotic functions of PXR are tumor-specific. Fibro-
blast growth factor 19 (FGF19) promotes liver carcinogen-
esis, and overexpression of the FGF receptor 1–4 strongly
correlates with neoplastic transformation in various cancers
[44-47]. Rifampicin-mediated PXR activation can signifi-
cantly enhance cell proliferation and tumor invasiveness
[48]. A previous study showed that the PXR-mediated cell
proliferative and metastatic phenotype was promoted by
FGF19 expression both in vitro and in vivo [48]. Further-
more, PXR can directly bind to the promoter region of
the FGF19 gene via DR3 and ER6 elements in both can-
cer and normal intestinal crypt cells. However, FGF19
signaling was only induced in colon cancer tissue, sug-
gesting a PXR tumor specific mechanism of proliferation
[48]. Table 2 summarizes the tissue-specific pro-proliferative
and anti-apoptotic functions of PXR; in these studies,
the activity of PXR was enhanced by PXR overexpressionnctions of PXR
ion approach References
oliferation and drug resistance. In SKOV-3 xenografts,
ell proliferation and tumor growth.
[33]
metastasis in human colon tumor cell lines and human
via PXR-mediated FGF19 signaling.
[48]
riptase PCR, and microarray analysis all revealed PXR
stic or stromal cells in breast carcinoma patient samples.
n of PXR via rifampicin increased PXR target genes





activation) or pharmacologic activation via rifampicin
d apoptosis. PXR activation in transgenic mice inhibited
sensitized mice to dimethylhydrazine-induced colon
ogenesis.
[35]
otected them from staurosporine-induced apoptosis via
hepatocytes. PXR agonists protected HepG2 human
poptosis via Bcl-2 and Bcl-xl induction.
[34]
813, increased resistance to chemotherapeutics paclitaxel
resistance and increased sensitivities to chemotherapeutics.
[32]
n apoptosis in the presence of paclitaxel or cisplatin.
e of paclitaxel, cisplatin, and medroxyprogesterone acetate.
[36]
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ligands, or reduced by PXR knockdown using small inter-
fering RNA.Pro-apoptotic and anti-proliferative properties of PXR
Apoptosis is a complex process involving various signal-
ing pathways and is both environment- and receptor/lig-
and-dependent. Interestingly, PXR has received attention
as a novel mediator of apoptosis via both p53-dependent
and -independent pathways. PXR expression is signifi-
cantly lower in colon cancer cell lines such as HCT116
and HT29 [49]. Ectopic expression of human PXR via
stable transfection significantly inhibited anchorage-
independent growth and cell proliferation both in vitro
and in vivo suggesting a novel physiological role of PXR
in protecting the cells from unregulated oncogenic pro-
liferation [50]. Moreover, p21 (WAF1/CIPI) expression
was significantly elevated, and G0/G1 cell cycle arrest
was induced by PXR. Therefore, the question remains:
Can PXR regulate p53-mediated tumor suppression?
Verma and colleagues [37] reported that various struc-
turally and functionally distinct PXR activators inhibited
cell proliferation in breast cancer cell lines MCF-7 and
ZR-75-1, both containing wild-type p53. In addition,
proliferative inhibition was induced by cell cycle arrest
at the G1/S phase followed by apoptosis [37]. When they
investigated which genes were responsible for decreased
growth, they found the pro-apoptotic genes, CDKN1A
(p21), BBC3 (PUMA) and Bax were all upregulated. This
study suggested that wild-type p53 was mechanistically
required for the anti-proliferative phenotype of PXR.
Moreover, PXR activators increased nitric oxide in these
cells via iNOS. To determine the biological significance
of PXR levels, PXR was knocked down via siRNA, which
reduced iNOS levels, decreasing apoptosis, suggesting a
PXR-mediated mechanism of apoptosis in breast cancer
cells. However, the role of PXR activation in breast can-
cer cells remains controversial. Similar to the aforemen-
tioned study, overexpression of PXR sensitized cells to
paraquat-induced oxidative stress when treated with a
PXR agonist [51]. The dependency of the anti-proliferative
effect of PXR on wild-type p53 suggested a functional re-
lationship between PXR and p53 signaling. Interestingly, a
recent report showed that p53 interacts with and inhibits
the function of PXR [52]. However, whether the functional
interaction between PXR and p53 leads to a mutual in-
hibitory effect, whether the PXR-p53 interaction is tissue
specific, and how stimulants of each pathway affect the
interaction and its biological significance still remain elu-
sive. Table 3 summarizes the tissue-specific pro-apoptotic
and anti-proliferative functions of PXR; in these studies,
the activity of PXR was induced either by constitutive acti-
vation or pharmacologically by using ligands of PXR.Regulation of PXR under different tissue and cellular
contexts
PXR is expressed mainly in liver, intestine, and colon tis-
sues [39]. However, PXR activation has been shown to
be tissue-specific, based on differential ligand availability
and intratumoral concentrations of endogenous steroid
hormones, which may also be PXR activators within cer-
tain tissues. The relationship between ligand availability
and PXR activation has been found to modulate estro-
gen accumulation and disease progression in hormone-
responsive neoplasms, such as breast and endometrial
cancers. For example, the positive correlation between
estrogen and breast cancer progression has been well
established [53]. However, the role of PXR activation has
recently received considerable attention [26]. The or-
ganic anion transporter polypeptide 1A2 (OATP1A2) is
a transporter of hormone conjugates, facilitating the cel-
lular uptake of hormones [54]. Initially, Miki and col-
leagues [26] found the expression of both PXR and
OATP1A2 in human breast carcinoma. Moreover, their
findings suggested that PXR and OATP1A2 were poten-
tial markers of dedifferentiation and disease progression.
Later, Meyer zu Schwabedissen and colleagues [55]
showed a direct relationship between the pathogenesis
of hormone-responsive breast cancer and increased es-
trogen accumulation via PXR mediated upregulation of
OATP1A2. Estrogen, particularly its intratumoral pro-
duction, contributes to the pathogenesis of endometrial
cancer. Aromatase converts androgen to estrone and is
expressed at higher levels in neoplastic endometrium
than in normal tissues [56-58]. Similarly, estrone sulfa-
tase converts estrone sulfate (E1S) into estrone and is
found in higher levels in endometrial cancer than in nor-
mal tissues [59]. Mechanistically, the activities of both
aromatase and estrone sulfatase serve as an active source
of biologically active estrogen within endometrial carcin-
oma tissues [56-59]. Interestingly, an earlier study
showed that OATP1A2 upregulation was tumor-specific
and mediated by PXR activation, resulting in enhanced
uptake of E1S, an estrogen metabolite, and upregulation
of estrogen-targeted genes [55]. Pharmacologically, util-
izing the PXR inhibitor A-792611, rifampicin-induced
estrogen receptor activity in estrogen receptor-positive
T47-D cells was significantly reduced, suggesting the
mechanistic feasibility of PXR antagonists as therapeutic
agents for breast cancer [55].
PXR is activated by various pharmaceutical agents,
however whether and how various metabolites of the
parental compound affect PXR activity can lead to differ-
ential effects. In addition, variants of the parental com-
pounds may regulate PXR activation in a tissue specific
manner. For example, vitamin E is known to exist in
various isoforms of either tocotrienols or tocopherols.
Zhou and colleagues [60] showed that isoforms of
Table 3 Anti-proliferative and pro-apoptotic functions of PXR
Anti-proliferative functions of PXR
Tissue specification PXR activation approach References
Colon cancer Ectopic expression of PXR significantly inhibited anchorage-independent growth and cell proliferation




PXR overexpression sensitized cells to paraquat-induced oxidative stress when treated with PXR agonists. [51]
Pro-apoptotic functions of PXR
Tissue specification PXR activation approach Reference
Breast cancer SXR activators inhibited cell proliferation and induced apoptosis in breast cancer cells. Wild-type p53 was
mechanistically required for the anti-proliferative phenotype of PXR.
[37]
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get genes in a tissue-specific manner. Target genes such
as CYP3A4, UGT1A1, and MDR1 were all induced in
primary hepatocytes; however, CYP3A4 could not be
induced in intestinal LS180 cells. Furthermore, nuclear
receptor co-repressor expression was higher in LS180
cells, suggesting that differential expression of co-factors
can contribute to alternative modes of activation in a tis-
sue specific manner [60].
Similar results have been seen in previous studies con-
cerning the importance of transcriptional co-activators
and co-repressors in regulating nuclear receptor activation
[61]. Nuclear receptor co-repressors and co-activators are
common and are shared among all nuclear receptors. The
p160 steroid receptor coactivator (SRC) family consists of
three members, SRC-1, SRC-2, and SRC-3. These co-
activators harbor acetyltransferase activity and bind to nu-
clear receptors to enhance their activity [62]. The SRC
family has been well-studied and is amplified or overex-
pressed in certain cancers. Misiti and colleagues [38]
found despite ubiquitous expression, nuclear receptor co-
activators and co-repressors are expressed at different
levels in a tissue-specific manner and therefore differen-
tially affect nuclear receptor-mediated gene activation and
hormonal regulation. Nevertheless, PXR expression is ele-
vated in several human cancers including colon, breast,
prostate, intestinal, esophageal, endometrial, and ovarian.
Thus, differential tissue expression of not only PXR but of
co-activators and co-repressors in human cancer makes
generalized treatment approaches a trend of the past and
personalized gene-based therapeutics a promising treat-
ment modality of the future.
Clinical relevance
PXR plays a pivotal role in the development of multi-
drug resistance via the induction of drug metabolizing
enzymes and transporters that mediate metabolism, de-
toxification, and elimination of most pharmaceutical
agents at clinically relevant concentrations. CYP3A4 is
an important mediator of drug metabolism and is tran-
scriptionally regulated by PXR. PXR also regulates drugefflux by inducing the expression of MDR1. This has ap-
plications in various steroid-dependent neoplasms, such
as breast and endometrial cancers that express higher
levels of PXR in neoplastic tissues than in normal tissues
[26,28]. Moreover, Miyoshi and colleagues [63] suggest
using intratumoral levels of CYP3A4/7 mRNA as predic-
tors of response to antineoplastic drugs such as doce-
taxel in the treatment of breast cancer; and further
involvement of the CYP3A family in drug clearance may
have subsequent effects on patient prognosis [28]. Thus,
a better understanding of the mechanisms that underlie
the involvement of PXR in regulating steroid metabolism
and the intratumoral steroid levels involved in the car-
cinogenesis of hormone-dependent cancers, as well as
PXR-mediated multidrug resistance, is needed. However,
the ability of PXR to promiscuously bind to various
structurally diverse compounds may cause targeting
ligand-mediated PXR activation to be a promising yet in-
tricate task to complete. When designing drugs to target
PXR-mediated activation, it is important to take into ac-
count the molecular network of PXR with other cellular
proteins and signaling pathways, including the molecular
cross-talk of PXR with other nuclear receptors such as
constitutive androstane receptor (CAR) that bind to similar
response elements and activate an overlapping set of genes.
Although concurrent administration of PXR antagonists
with traditional chemotherapeutic drugs may circumvent
drug-drug interactions and toxicities, the consideration of
documented bone demineralization, unanticipated hyper-
sensitiveness and toxicities associated with such combina-
tions must not be disregarded.
Paclitaxel is a traditional chemotherapeutic known to
activate PXR and enhance MDR1-mediated drug clear-
ance. Interestingly, docetaxel, a related antineoplastic
agent, does not activate PXR and mechanistically cannot
displace transcriptional corepressors from PXR. This
suggests the importance of modulating PXR activity as a
mechanism to regulate drug metabolism and efficiency
as well as clearance. Nonetheless, previous studies have
assessed the clinical application of PXR modulators to
sensitize cells to chemotherapeutic drugs. Some of the
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nazole, HIV protease inhibitor A-792611, coumestrol,
and FLB-12.
Ketoconazole
Ketoconazole [64], a PXR antagonist first described by
Takeshita and colleagues [65], disrupts the binding of
co-regulators, both activators and repressors, to the sur-
face of PXR in an agonist-dependent manner. This com-
pound has been shown to initiate non-competitive
inhibition with PXR agonists by inhibiting PXR’s associ-
ation with its co-activator SRC-1 [64-67]. Moreover, Wang
and colleagues showed the importance of the AF-2 region
located outside of the PXR LBD in the mechanistic inhib-
ition of PXR by ketoconazole. However, ketoconazole has
pleiotropic effects on cellular targets and unpredictable
kinetics [68-72]. Thus, more target-specific drugs are
needed to antagonize PXR activation.
Enilconazole
Enilconazole [67], a ketoconazole derivative, has signifi-
cant inhibitory effects on rifampicin-activated human
PXR in the presence of paclitaxel. It has been considered
an “activating antagonist” due to its ability to modestly
induce activation of PXR alone, but it has been shown to
significantly inhibit PXR in the presence of a PXR
agonist.
HIV protease inhibitor A-792611
Some HIV protease inhibitors are also potent CYP3A4
inhibitors; however, like enilconazole, these compounds
can also induce PXR activation, yet the inhibitory effects
on CYP3A4 activity outweigh the agonistic effects on
PXR. Examples of such compounds include HIV protease
inhibitors such as ritonavir [73]. The novel HIV protease
inhibitor (s)-1-[(1 S, 3S, 4S)-4-[(S)-2-(3-benzyl-2-oxo-
imidazolidin-1-yl)-3,3-dimethyl-butyrylamino]-3-hydroxy-
5-phenyl-1-(4-pyridin-2-yl-benzyl)-pentylcarbamoyl]-2,
2-dimethyl-propyl-carbamic acid methyl ester (A-792611)
is mainly metabolized by CYP3A4 but is also an inhibitor
of CYP3A4 activity [74]. Healan-Greenberg [74] reported
target specific effects of A-792611 on PXR and no effects
on other nuclear receptors that regulate P450s such as
CAR and farnesoid X receptor. Thus, A-792611 was re-
ported to be a functional antagonist of PXR in human but
not rat hepatocytes [74].
Coumestrol
Coumestrol [75], a naturally occurring phytoestrogen, is a
member of the isoflavonoid family. Wang and colleagues
[75] demonstrated that coumestrol suppressed SR12813-
mediated PXR induction of CYP3A4 and CYP2B6 in
primary human hepatocytes. Furthermore, the natur-
ally occurring phytoestrogen antagonized co-regulatorrecruitment with a mechanism similar to that of keto-
conazole, binding outside the ligand binding pocket. Ekins
and colleagues [76] utilized computational models to sug-
gest that coumestrol could bind at the AF-2 domain of
PXR. However, poor solubility of coumestrol is a disadvan-
tage [75]. Therefore, the clinical use of coumestrol re-
quires further investigation.
FLB-12
Venkatesh and colleagues [77] successfully characterized
and developed a novel azole analogue [1-(4-(4-(((2R,4S)-2-
(2,4-difluorophenyl)-2-methyl-1,3-dioxolan-4-yl)methoxy)
phenyl)piperazin-1-yl)ethanone (FLB-12)]. Similar to
those of A-729611, the targeted effects of FLB-12 are PXR-
specific, with no effects on other orphan nuclear receptors
[77]. Interestingly, they reported that the small-molecule
FLB-12 was significantly less toxic than other PXR antago-
nists such as ketoconazole; and decreased acetaminophen
hepatotoxicity in vivo. Likewise, FLB-12 induced additional
effects by preventing resistance to 7-ethyl-10-hydroxy-
camptothecin (SN-38) in colon cancer cells [77]. Thus, this
class of compounds encourages the design and develop-
ment of PXR-targeted antagonists that can inhibit drug re-
sistance, with limited toxicity, to enhance chemosensitivity
and therapeutic efficacy with clinical significance.
Conclusions
Overall, there are two paradigms of signaling to be targeted
in regards to PXR activation 1) PXR-mediated signaling in
drug metabolism and 2) PXR-mediated signaling in cell
proliferation, apoptosis and tumor aggressiveness, which
opens numerous avenues for targeted therapeutic applica-
tion. Therefore, identifying significant biomarkers within
the dichotomy of PXR signaling could optimize strategies
for designing potential PXR antagonists with tissue-
specific, desirable outcomes. Nevertheless, the therapeutic
outcome of a drug depends on multiple variables. However,
in regard to PXR, differential tissue-specific expression of
the protein, and its co-regulators may play a significant role
in drug bioavailability in non-neoplastic versus neoplastic
tissues, as well as modulation of the drug’s mechanism
of action at tumor sites. Together, taking into consider-
ation these aspects of PXR tissue specific regulation,
and identifying novel small molecules that produce the
desired effect with limited toxicities will lead to the de-
sign and characterization of PXR-targeted small molecules
with significant tissue-specific, pharmacologic properties.
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